Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for Exudative Retinal Detachment in Uveal Melanoma
NCT04082962Phase 1Completed
- Start
- Dec 2018
- Primary completion
- Dec 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ozurdex in retinal detachment (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events Related to the Implant at 12 months. Started Dec 2018; status: completed.
02
Drugs
ozurdex
03
Conditions
retinal detachment
Beyond the preview
Go deeper on NCT04082962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082962.